Deformed Fingernail

News
Poll

Is thyroid hormone medication associated with nail plate deformity, or is something else going on?

A 55-year-old woman seeks treatment of a deformed, slightly tender nail plate and swollen, erythematous nail folds; she first noticed the condition several months earlier. The only medication she takes is thyroid hormone.

What is your initial approach?

Measure the patient's thyroxine level
Measure the patient's thyroid-stimulating hormone level
Order a bacterial culture
Order a fungal culture
Order a radiograph of the finger
Related Content
Lebrikizumab Found Safe, Effective in Patients With Skin of Color With AD: Daily Dose / image credit: ©New Africa/AdobeStock

Lebrikizumab Found Safe, Effective in Patients With Skin of Color With AD: Daily Dose

Sydney Jennings
July 15th 2025
Article

Your daily dose of the clinical news you may have missed.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
July 8th 2025
Podcast

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression / image credit ©martialred/stock.adobe.com

Mental Health Burden in Atopic Dermatitis: Study Identifies Key Risk Factors for Anxiety and Depression

Grace Halsey
July 2nd 2025
Article

Depression and anxiety affect as many as 1 in 4 people with AD, with pruritus, sleep disorders, education level, and comorbidities identified as independent risk factors.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Investigational Respegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

Grace Halsey
June 25th 2025
Article

In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid in Adults

Sydney Jennings
June 20th 2025
Article

Dupilumab is the first targeted treatment for BP to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

© 2025 MJH Life Sciences

All rights reserved.